1. A method of eliciting protective immunity against Norovirus in a human comprising the steps of:
(i) intramuscularly administering to the human a vaccine comprising Norovirus virus-like particles (VLPs), wherein the Norovirus
VLPs are present in the vaccine in an amount of 1 ?g to 200 ?g, wherein the vaccine comprises at least one adjuvant that is
not a bacterially-derived exotoxin adjuvant, and wherein the administration of the vaccine elicits production of Norovirus-specific
functional antibodies in a blood sample from the human; and

(ii) measuring the Norovirus-specific functional antibodies in the blood sample from the human, wherein a geometric mean serum
titer of the Norovirus-specific functional antibodies greater than 40 as measured by a carbohydrate blocking assay is indicative
of protective immunity.